Eksklusiv menneskemelk hos premature nyfødte og tidlig vaskulære aldringsrisikofaktorer (NEOVASC) (NEOVASC)
Effekter av et eksklusivt diett med menneskemelk hos premature nyfødte på tidlig vaskulære aldringsrisikofaktorer (NEOVASC)
Early vascular aging has its origins in fetal and neonatal life. The NEOVASC clinical trial aims to determine the effects of an exclusive human milk diet in extremely preterm infants on long-term cardiovascular health.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Early vascular aging has its origins in fetal and neonatal life. This early period of life plays an important role in the development of obesity, high blood pressure, abnormalities in lipid metabolism and non-insulin dependent diabetes. Increased cardiovascular risk in formerly preterm infants constitutes a health problem of steadily growing relevance. Emerging evidence suggests that human milk feeding has substantial benefits to the health of all infants, especially for those born prematurely. Unfortunately, human milk alone does not provide sufficient concentrations of nutrients, especially calcium, phosphorus, protein, and fat needed for these infants to grow satisfactorily. For that purpose, fortifiers are used to help increase the nutritional value of human milk.
The NEOVASC study is a multicentric, prospective, randomized, controlled, open and parallel group clinical trial. A total of 200 extremely preterm infants and 100 term infants are recruited for the test and control group, respectively. Infants in the test group (i.e., premature neonates) are randomized to either:
- An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and a human milk fortifier until 36 weeks of gestation; OR
- Human milk (as long as available) and a human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.
After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included. Participants within this control group are not enrolled at the time of birth but instead recruited in various kindergartens at the age of five. Therefore, data from birth is taken from the mother-child-booklet, which contains clinical records about the pregnancy, birth and early life of children born in Austria. The total study duration is scheduled for 96 months with a recruitment phase of 36 months. Follow-up visits are planned at one, two and five years of age for the test group.
The purpose of the NEOVASC clinical trial is to characterize early life stressors by assessing the effects of a physiological (i.e., human milk-based) nutrition in extremely preterm infants during the vulnerable preterm period on the risk of metabolic and vascular complications in later life. Outcomes include predictors and intermediate components of cardiovascular disease.
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Ursula Kiechl-Kohlendorfer, MD, MSc
- Telefonnummer: +43 512 504 27309
- E-post: ursula.kohlendorfer@i-med.ac.at
Studer Kontakt Backup
- Navn: Wolfgang Mitterer, MD
- Telefonnummer: +43 670 2021490
- E-post: wolfgang.mitterer@student.i-med.ac.at
Studiesteder
-
-
Tyrol
-
Innsbruck, Tyrol, Østerrike, A-6020
- Rekruttering
- Medical University of Innsbruck
-
Ta kontakt med:
- Ursula Kiechl-Kohlendorfer, MD, MSc
- Telefonnummer: +43 512 504 27309
- E-post: ursula.kohlendorfer@i-med.ac.at
-
Ta kontakt med:
- Wolfgang Mitterer, MD
- E-post: wolfgang.mitterer@student.i-med.ac.at
-
Hovedetterforsker:
- Christoph Binder, MD
-
Hovedetterforsker:
- Martin Wald, MD
-
Hovedetterforsker:
- Burkhard Simma, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Preterm-born group:
Inclusion Criteria:
- Extremely preterm infants with a birth weight of 500-1250g.
- Feeding is NPO or exclusive human milk prior to enrollment.
- Parent(s) willing to sign informed consent.-
Exclusion Criteria:
- Infants with a birth weight <500g or >1250g
- Subjects diagnosed with inborn errors of metabolism such as galactosemia, phenylketonuria
- Subjects who have not been NPO or fed exclusive human milk diet prior to enrollment.
- Presence of major congenital malformation.
- Presence of intestinal perforation or Stage 2 Necrotizing enterocolitis prior to enrollment.
- Parent(s) not willing to sign informed consent.
- Unable to participate for any reason based on the decision of the study investigator (e.g. unlikely to survive the study period).
Term-born group:
Inclusion criteria
- Term-born children with an adequate birth weight
- Parent(s) willing to sign informed consent
Exclusion criteria
- Subjects with acute or chronic illness
- Parent(s) not willing to sign informed consent
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Aktiv komparator: Randomized study product group
receiving study product (human milk fortifier "Humavant") until a gestational age of 36 weeks |
Premature infants are randomized to either:
After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included. |
|
Aktiv komparator: Randomized control group
receiving study product until a gestational age of 32 weeks and reference product (bovine based fortifier or bovine formula) after 32 weeks of gestation |
Premature infants are randomized to either:
After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included. |
|
Ingen inngripen: Term control group
Term-born controls as a reference group for outcome parameters |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Fasting blood glucose
Tidsramme: "First day of life" up to "five years of life"
|
Primary outcome is the difference in fasting blood glucose at five years of age |
"First day of life" up to "five years of life"
|
|
Blood pressure
Tidsramme: "First day of life" up to "five years"
|
Primary outcome is the difference in blood pressure at five years of age |
"First day of life" up to "five years"
|
|
Distensibility of aorta
Tidsramme: "First day of life" up to "five years"
|
Primary outcome is the difference in the distensibility of the descending aorta using validated echocardiographic protocols at five years of age |
"First day of life" up to "five years"
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Fasting blood glucose
Tidsramme: "First day of life" up to "24 months"
|
Secondary outcome is fasting glucose at a corrected age of one and two years. |
"First day of life" up to "24 months"
|
|
Blood pressure
Tidsramme: "First day of life" up to "24 months"
|
Secondary outcome is blood pressure at a corrected age of one and two years. |
"First day of life" up to "24 months"
|
|
BMI
Tidsramme: "First day of life" up to "five years"
|
Secondary outcome is BMI at five years of age, weight in kilograms and height in meters will be combined to report BMI in kg/m2 |
"First day of life" up to "five years"
|
|
Insulin sensitivity
Tidsramme: "First day of life" up to "five years"
|
Secondary outcome is insulin sensitivity at five years of age |
"First day of life" up to "five years"
|
|
Lipid profile
Tidsramme: "First day of life" up to "five years"
|
Secondary outcome is lipid profile at five years of age |
"First day of life" up to "five years"
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Fasting blood glucose
Tidsramme: "five years of age"
|
Difference in fasting blood glucose between preterm- and term-born children at five years of age |
"five years of age"
|
|
Blood pressure
Tidsramme: "five years of age"
|
Difference in blood pressure between preterm- and term-born children at five years of age |
"five years of age"
|
|
Distensibility of the descending aorta
Tidsramme: "five years of age"
|
Difference in the distensibility of the descending aorta between preterm- and term-born children using validated echocardiographic protocols at five years of age Results will be compared to results of term-born children |
"five years of age"
|
|
BMI
Tidsramme: "five years of age"
|
Difference in BMI between preterm- and term-born children at five years of age, weight in kilograms and height in meters will be combined to report BMI in kg/m2 |
"five years of age"
|
|
Insulin sensitivity
Tidsramme: "five years of age"
|
Difference in insulin sensitivity between preterm- and term-born children at five years of age |
"five years of age"
|
|
Lipid profile
Tidsramme: "five years of age"
|
Difference in lipid profile between preterm- and term-born children at five years of age |
"five years of age"
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Etterforskere
Etterforskere
- Hovedetterforsker: Ursula Kiechl-Kohlendorfer, MD, MSc, Medical University Innsbruck
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- NEOVASC
- 868624 (Annet stipend/finansieringsnummer: Austrian Research Promotion Agency)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .